Sagimet Biosciences Inc.
SGMT
$10.55
$1.2713.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 20.72% | 23.82% | -12.01% | -53.72% | -103.01% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.77% | 58.17% | 54.09% | 47.72% | 2.33% |
| Change in Net Operating Assets | -2,228.21% | -290.09% | -0.48% | 238.32% | -87.84% |
| Cash from Operations | 23.06% | 21.74% | -7.58% | -16.49% | -137.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 5.36% | 118.54% | 107.39% | 100.05% | 100.65% |
| Cash from Investing | 5.36% | 118.54% | 107.39% | 100.05% | 100.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 17,546,200.00% | -- | -99.74% | -99.75% | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Financing | 16,466,200.00% | 1,118.52% | -99.74% | -99.74% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 330.40% | 74.93% | -5,922.97% | -79.31% | -169.25% |